medigraphic.com
ISSN 1561-3062 (Electronic)

2021, Number 4

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2021; 47 (4)

Risk of persistence post-treatment of cervical intraepithelial neoplasia with HPV infection 16

Garví MJ, Lara PR, Plitt SJ, Sánchez GD, Vázquez VV, Martínez CJP

Language: Spanish
References: 31
Page:
PDF size: 356.92 Kb.


ABSTRACT

Introduction: The oncogenesis process for the development of high-grade cervical lesions requires persistent infection of a high-risk human papillomavirus, among which HPV16 is the subtype with the lowest clearing rate.
Objective: To determine if HPV16 infection prior to conization is a risk factor for the persistence of the precursor lesion after treatment.
Methods: In February 2020, a systematic review was carried out on the persistence of disease after LEEP/LLETZ in patients with HPV16 infection prior to treatment. A search was performed in the pubic-medline databases of the National Center of Biotechnology Information (NCBI) and ClinicalTrial.gov of the National Library of Medicine, both in the US. 418 articles were obtained, of which 8 were eligible. All were retrospective cohort. Four articles discussed significant relationship between the presence of infection with HPV16 in the controls prior to conization, and the risk of treatment failure; the remaining four did not talk over this relationship.
Conclusions: There is no agreement in the literature on whether HPV16 infection prior to treatment is an independent factor of lesion persistence. More studies are required, with larger population, to determine if positive HPV16 prior to treatment serves to identify a group at risk of treatment failure.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492

  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. Septiembre 1999;189(1):12-9. DOI: https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

  3. Giorgi-Rossi P, Franceschi S, Ronco G. HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer. 2012;130(6):1387-94. DOI: https://doi.org/10.1002/ijc.26147

  4. Nam K, Chung S, Kim J, Jeon S, Bae D. Factors associated with HPV persistence after conization in patients with negative margins. J Gynecol Oncol. 2009;20(2):91-5. DOI: https://doi.org/10.3802/jgo.2009.20.2.91

  5. Byun JM, Jeong DH, Kim YN, Jung EJ, Lee KB, Sung MS, et al. Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia. Medicine (Baltimore). 2018;97(51):e13606. DOI: https://doi.org/10.1097/MD.0000000000013606

  6. Yu Y, Han L, Yu W, Duan Y, Wang Z, Hu H, et al. High risk factors associated with HPV persistence after loop electrosurgical excision procedure in patients with intraepithelial neoplasia. Int J Clin Exp Pathol. 2017;10:1817-24.

  7. Malapati R, Chaparala S, Cejtin HE. Factors influencing persistence or recurrence of cervical intraepithelial neoplasia after loop electrosurgical excision procedure. J Low Genit Tract Dis. 2011;15(3):177-9. DOI: https://doi.org/10.1097/LGT.0b013e3181fee61d

  8. Fernández-Montolí ME, Tous S, Medina G, Castellarnau M, García-Tejedor A, de Sanjosé S. Long-term predictors of residual or recurrent cervical intraepithelial neoplasia 2-3 after treatment with a large loop excision of the transformation zone: a retrospective study. BJOG Int J Obstet Gynaecol. 2020;127(3):377-87. DOI: https://doi.org/10.1111/1471-0528.15996

  9. Chen L, Liu L, Tao X, Guo L, Zhang H, Sui L. Risk Factor Analysis of Persistent High-Grade Squamous Intraepithelial Lesion After Loop Electrosurgical Excision Procedure Conization. J Low Genit Tract Dis. 2019;23(1):24-7. DOI: https://doi.org/10.1097/LGT.0000000000000444

  10. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103(18):1387-96. DOI: https://doi.org/10.1093/jnci/djr283

  11. Palmer JE, Ravenscroft S, Ellis K, Crossley J, Dudding N, Smith JH, et al. Does LLETZ excision margin status predict residual disease in women who have undergone post-treatment cervical cytology and high-risk human papillomavirus testing? Cytopathol Off J Br Soc Clin Cytol. 2016;27(3):210-7. DOI: https://doi.org/10.1111/cyt.12260

  12. Urrútia G, Bonfill X. [PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses]. Med Clin (Barc). 2010;135(11):507-11. DOI: https://doi.org/10.1016/j.medcli.2010.01.015

  13. Kang WD, Kim SM. Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women. Menopause N Y N. 2016;23(1):81-6. DOI: https://doi.org/10.1097/GME.0000000000000488

  14. Lara-Peñaranda R, Rodríguez-López PM, Plitt-Stevens J, Ortiz-González A, Remezal-Solano M, Martínez-Cendán JP. Does the trend toward less deep excisions in LLETZ to minimize obstetric risk lead to less favorable oncological outcomes? Int J Gynaecol Obstet. Dec 2020;148(3):316-24. DOI: https://doi.org/10.1002/ijgo.13080

  15. Ku CH, Lee SH, Lee SP. Effect of human papillomavirus genotype on severity and prognosis of cervical intraepithelial neoplasia. Obstet Gynecol Sci. 2014;57(1):37-43.

  16. Bruno MT, Cassaro N, Garofalo S, Boemi S. HPV16 persistent infection and recurrent disease after LEEP. Virol J. 2019;16(1):148.

  17. Wu J, Jia Y, Luo M, Duan Z. Analysis of Residual/Recurrent Disease and Its Risk Factors after Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia. Gynecol Obstet Invest. 2016;81(4):296-301. DOI: https://doi.org/10.1159/000437423

  18. Ryu A, Nam K, Kwak J, Kim J, Jeon S. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. J Gynecol Oncol. 2012;23(4):217-25. DOI: https://doi.org/10.3802/jgo.2012.23.4.217

  19. Wu D, Zheng Y, Chen W, Guo C, Yu J, Chen G, et al. Prediction of residual/recurrent disease by HPV genotype after loop excision procedure for high-grade cervical intraepithelial neoplasia with negative margins. Aust N Z J Obstet Gynaecol. 2011;51(2):114-8. DOI: https://doi.org/10.1111/j.1479-828X.2010.01280.x

  20. Kang WD, Oh MJ, Kim SM, Nam JH, Park CS, Choi HS. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol. 2010;203(1):72.e1-6. DOI: https://doi.org/10.1016/j.ajog.2010.01.063

  21. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathol Off J Br Soc Clin Cytol. 2009;20(1):5-16. DOI: https://doi.org/10.1111/j.1365-2303.2008.00636.x

  22. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006;15(5):908-14. DOI: https://doi.org/10.1158/1055-9965.EPI-05-0845

  23. Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S. Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori. 2004;90(2):225-8. DOI: https://doi.org/10.1177/030089160409000211

  24. Torné A, Fusté P, Rodríguez-Carunchio L, Alonso I, del Pino M, Nonell R, et al. Intraoperative post-conisation human papillomavirus testing for early detection of treatment failure in patients with cervical intraepithelial neoplasia: a pilot study. BJOG Int J Obstet Gynaecol. March 2013;120(4):392-9. DOI: https://doi.org/10.1111/1471-0528.12072

  25. Du R, Meng W, Chen ZF, Zhang Y, Chen SY, Ding Y. Post-treatment human papillomavirus status and recurrence rates in patients treated with loop electrosurgical excision procedure conization for cervical intraepithelial neoplasia. Eur J Gynaecol Oncol. 2013;34(6):548-51.

  26. Nam K, Chung S, Kim J, Jeon S, Bae D. Factors associated with HPV persistence after conization in patients with negative margins. J Gynecol Oncol. 2009;20(2):91-5. DOI: https://doi.org/10.3802/jgo.2009.20.2.91

  27. Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer. 2011;129(4):903-9. DOI: https://doi.org/10.1002/ijc.25745

  28. Kocken M, Uijterwaal MH, de Vries ALM, Berkhof J, Ket JCF, Helmerhorst TJM, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125(2):500-7. DOI: https://doi.org/10.1016/j.ygyno.2012.01.015

  29. Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017;18(12):1665-79. DOI: https://doi.org/10.1016/S1470-2045(17)30700-3

  30. Gök M, Coupé VMH, Berkhof J, Verheijen RHM, Helmerhorst TJM, Hogewoning CJA, et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol. 2007;104(2):273-5. DOI: https://doi.org/10.1016/j.ygyno.2006.10.011

  31. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG Int J Obstet Gynaecol. 2006;113(11):1303-7. DOI: https://doi.org/10.1111/j.1471-0528.2006.01063.x




2020     |     www.medigraphic.com